221 related articles for article (PubMed ID: 28653251)
41. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
42. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
43. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
[TBL] [Abstract][Full Text] [Related]
44. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
45. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
46. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Suenaga M; Mizunuma N; Chin K; Matsusaka S; Shinozaki E; Oya M; Ueno M; Yamaguchi T; Muto T; Konishi F; Hatake K
Surg Today; 2009; 39(1):27-31. PubMed ID: 19132464
[TBL] [Abstract][Full Text] [Related]
48. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
50. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
[TBL] [Abstract][Full Text] [Related]
51. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
52. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
[TBL] [Abstract][Full Text] [Related]
53. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
Li T; Wang B; Wang Z; Ragaz J; Zhang J; Sun S; Cao J; Lv F; Wang L; Zhang S; Ni C; Wu Z; Xie J; Hu X
PLoS One; 2015; 10(7):e0133133. PubMed ID: 26186012
[TBL] [Abstract][Full Text] [Related]
54. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
55. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.
Shin DY; Choi YH; Lee HR; Na II; Yuh YJ; Kim BS; Chung IJ; Bae WK; Shim HJ; Song EK; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2016 Jan; 77(1):163-8. PubMed ID: 26589790
[TBL] [Abstract][Full Text] [Related]
56. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
[TBL] [Abstract][Full Text] [Related]
57. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
[TBL] [Abstract][Full Text] [Related]
58. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Wainberg ZA; Messersmith WA; Peddi PF; Kapp AV; Ashkenazi A; Royer-Joo S; Portera CC; Kozloff MF
Clin Colorectal Cancer; 2013 Dec; 12(4):248-54. PubMed ID: 24075777
[TBL] [Abstract][Full Text] [Related]
59. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
60. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
